Design Therapeutics (DSGN) stock
Follow DSGN's trial news. Pro members can get an alert when Design Therapeutics files news, and see its trials, share raises, and its CEO's filings.
What's next for DSGN, and how long its cash lasts
From Design Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
The company says its cash lasts into 2029 (8-K, Apr 28).
Dilution on the horizon
- Shelf registration (S-3, filed May 7, 2025)
- At-the-market share sales program (S-3, filed May 7, 2025)
Insiders
No open-market buys or sales by its officers or directors in their filings of the last year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 28 daysINOInovio Pharmaceuticals
INOINO-3107
- In 39 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 51 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why DSGN scores 0
Below AverageTrending up, 1 of 14 checks firingWhat the Quality Score means
- +1Chart checks 1 of 14 firing right now, one point each
- +2Long-term trend above a rising 200-day average
- Profit subtracts
- Volatility subtracts
- Cash flow subtracts
What's next
Expected to report Thu Nov 5, before the open
After its last 4 reports it closed +7.3% on average, higher 3 of 4 times.
What would turn DSGN's score around: 7 things, for Pro members
Here is what Pro members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
DSGN has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1438.3
- MACD (12, 26, 9)Below signal
- 50-day average$13.78
- 200-day average$12.01
- ADX 1424.8
- Support$11.94
- Resistance$13.54
- Bollinger Bands (20, 2)Inside
- Volume0.4x
How DSGN ranks in Biotech
DSGN is #126 of 276 by Quality Score. The top three are shown with their scores, and more by name.
KNSA7/1418
ABCL6/1416
OABI9/1415
DNLIOpen for its score
DNTHOpen for its score
EBSOpen for its score
EIKNOpen for its score
DSGN1/140
When does DSGN report earnings, and what happens after?
Expected to report Thu Nov 5, before the open (in 34 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 3, 2026Before open | Before open | -1.1% | +4.8% | +14.9% |
| Apr 28, 2026After close | After close | +1.5% | +23.3% | +4.7% |
| Mar 9, 2026After close | After close | +1.6% | -3.7% | +6.0% |
| Nov 5, 2025After close | After close | -1.7% | +4.9% | +16.2% |
About Design Therapeutics
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of DSGN's score, with the points and the reason
- All 14 checks on DSGN and on all 2,958 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on DSGN
Straight Answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.